CLAIMS

1. A pharmaceutical composition adapted for treating a paediatric neurological disorder, said composition comprising the following cannabinoids:
w/w %
CBDA 40-60%;
CBD 1-5%;
CBG 1-10%;
CBDP 1-5%;
CBDB 1-5%;
CBGA 1-10%;
CBN 1-3%
THC <1%; and

together with a pharmaceutically acceptable carrier.

2. A dosage form adapted for treating a paediatric neurological disorder, said dosage form comprising the following composition:
w/w %
CBDA 40-60%;
CBD 1-5%;
CBG 1-10%;
CBDP 1-5%;
CBDB 1-5%;
CBGA 1-10%;
CBN 1-3%
THC <1%; and

wherein the CBDA component of the composition is selected from the group consisting of: between 1mg and 1000mg; between 1mg and 500mg; between 1 and 100mg; less than 400mg; less than 300mg; less than 200mg and less than 100mg.

3. A dosage form adapted for treating a paediatric neurological disorder, said dosage form comprising the following composition:
w/w %
CBDA 40-60%;
CBD 1-5%;
CBG 1-10%;
CBDP 1-5%;
CBDB 1-5%;
CBGA 1-10%;
CBN 1-3%
THC <1%; and

wherein the CBDA component of the composition is selected from the group consisting of: 600mg; 400mg; 300mg; 200mg; 100mg; 50mg; 10mg; 5mg; 2mg; and 1mg.

4. A kit adapted for treating a paediatric neurological disorder, said kit comprising the following composition:
w/w %

CBDA 40-60%;
CBD 1-5%;
CBG 1-10%;
CBDP 1-5%;
CBDB 1-5%;
CBGA 1-10%;
CBN 1-3%
THC <1%; and

together with instructions for use.

5. Use of a composition comprising the following cannabinoids:
w/w %
CBDA 40-60%;
CBD 1-5%;
CBG 1-10%;
CBDP 1-5%;
CBDB 1-5%;
CBGA 1-10%;
CBN 1-3%
and
THC <1%;
in the manufacture of a medicament for the treatment of a paediatric neurological disorder.

6. The use of claim 5, wherein the cannabinoids of the composition are present in amounts selected from the group consisting of:

Composition 1 comprising
w/w %
CBDA 50%;
CBD 2%;
CBG 5%;
CBDP 2%;
CBDB 2%;
CBGA 5%;
CBN 3% and
THC <0.3%;

and

Composition 2 comprising
w/w %
CBDA 45%;
CBD 1%;
CBG 4%;
CBDP 1%;
CBDB 2%;
CBGA 4%;
CBN 2% and
THC <0.2%.

7. The use of claim 5 or 6, wherein the paediatric neurological disorder is selected from the group consisting of: PANS/PANDAS, Tourette syndrome, cerebral palsy, ataxia, attention deficit hyperactivity disorder (ADHD), Lennox Gastaut, Dravet syndrome,

leukodystrophy and subtypes, Reye syndrome, Rett syndrome, Fragile-X syndrome, Phelan-McDermid syndrome, Angelman syndrome, Pitt-Hopkins syndrome, Prader-Willi syndrome, a metabolic disorder and a glycosylation disorder.

8. The use of claim 7, wherein the PANS is selected from the group consisting of: PANDAS and PITAND.

9. The use of any one of claims 5 to 8, wherein the composition further comprises an oil selected from the group consisting of: a synthetic oil; plant based oil; mineral oil; canola oil; and olive oil.

10. The use of any one of claims 5 to 9, wherein the composition comprises less than 5% w/w terpenes.

11. The use of any one of claims 5 to 9, wherein the composition comprises less than 2% w/w organic plant material.

12. The use of any one of claims 5 to 9, wherein the composition comprises less than 2% w/w of plant phenols.

13. The use of any one of claims 5 to 12, wherein the cannabinoid component of the composition is selected from the group consisting of: between 1 and 500mg/ml; between 10 and 100mg/ml; be at a concentration of 50mg/ml.

14. The use of any one of claims 5 to 13, wherein the CBDA component of the composition is selected from the group consisting of: between 1 and 500mg/ml; between 10 and 100mg/ml; be at a concentration of 50mg/ml.

15. The use of any one of claims 5 to 14, wherein the composition further comprises an additional active ingredient.

16. The use of claim 15, wherein the additional active ingredient is selected from the group consisting of: diclofenac, prednisone, celecoxib and psylocibin.